

# **ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 44**

*Sponsored by the Division of Medicinal Chemistry  
of the American Chemical Society*

*Editor-in-Chief: **JOHN E. MACOR***

BRISTOL-MYERS SQUIBB, R&D  
WALLINGFORD, CT, USA



---

*Annual Reports in*  
**MEDICINAL CHEMISTRY**

VOLUME **44**

---

*Sponsored by the Division of Medicinal  
Chemistry of the American Chemical Society*

Editor-in-Chief

**JOHN E. MACOR**

*Neuroscience Discovery Chemistry  
Bristol-Myers Squibb  
Wallingford, CT, United States*

Section Editors

*ROBICHAUD • STAMFORD • BARRISH • MYLES •  
PRIMEAU • LOWE • DESAI*



Amsterdam • Boston • Heidelberg • London • New York • Oxford  
Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo  
Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
Linacre House, Jordan Hill, Oxford OX2 8DP, UK  
84 Theobald's Road, London WC1X 8RR, UK  
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands  
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA  
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

First edition 2009

Copyright © 2009 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher.

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [permissions@elsevier.com](mailto:permissions@elsevier.com). Alternatively you can submit your request online by visiting the Elsevier web site at <http://www.elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*.

#### Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

ISBN: 978-0-12-374766-2  
ISSN: 0065-7743

For information on all Academic Press publications  
visit our web site at [www.elsevierdirect.com](http://www.elsevierdirect.com)

Printed and bound in USA

09 10 11 12 13 10 9 8 7 6 5 4 3 2

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation

---

*Annual Reports in*  
**MEDICINAL CHEMISTRY**

VOLUME **44**

---

## CONTRIBUTORS

Neel K. Anand	339	James N. Leonard	149
Jan D. Andersson	501	Shawn Maddaford	27
Subhash C. Annedi	27	Jürgen Maibaum	105
Gregory S. Bisacchi	379	Carl L. Manthey	211
Robert M. Borzilleri	301	Dennis J. McCarthy	501
Bruce D. Car	555	Nicholas A. Meanwell	397
Jotham W. Coe	71	Karen Miller-Moslin	323
John Gaetano D'Angelo	359	Terry W. Moore	443
Gene M. Dubowchik	3	Bernard P. Murray	535
Jacques Dumas	379	John M. Nuss	339
Charles S. Elmore	515	Brian T. O'Neill	71
David L. Feldman	105	Stefan Peukert	323
William R. Foster	555	M. Edward Pierson	501
Robert G. Gentles	3	William J. Pitts	247
Christer Halldin	501	Mark R. Player	211
Sangdon Han	227	Mimi L. Quan	189
Simon N. Haydar	51	Suman Rakhit	27
Shridhar Hegde	577	Jailall Ramnauth	27
Christopher Paul Hencken	359	Hans Rollema	71
Warren D. Hirst	51	Stefan U. Ruepp	555
Shuanghua Hu	3	Thomas Ryckmans	129
Robert M. Jones	149, 227	Arthur T. Sands	475
John F. Kadow	397	Michelle Schmidt	577
Alvin Solomon Kalinda	359	Paul M. Scola	397
Rao Kalla	265	Joanne M. Smallheer	189
John A. Katzenellenbogen	443	Roland G.W. Staal	51

Nicole van Straten	171	Dolatrai M. Vyas	281
Jayant Thatte	227	Stephen T. Wroblewski	247
Thomas N. Thompson	459	Mark D. Wittman	281
Marco Timmers	171	Heedong Yun	51
Amy Lew Tsuhako	339	Jeff Zablocki	265
Upender Velaparthi	281	Brian P. Zambrowicz	475
Gregory D. Vite	301		

## PREFACE

*Annual Reports in Medicinal Chemistry* has reached Volume 44. I hope that it continues to be *the* review resource for medicinal chemists. Volume 44 continues the traditions of *Annual Reports in Medicinal Chemistry* with 28 chapters covering the themes of central nervous system disease, cardiovascular and metabolic diseases, inflammation/pulmonary/gastrointestinal (GI), oncology, infectious disease, topics in biology, topics in drug design and discovery and finally our review of new drugs introduced in 2008 in the "To Market, To Market" section. I am particularly pleased that Volume 44 contains three case histories detailing the discovery and development of varenicline for smoking cessation, aliskerin for hypertension and ixabepilone for cancer. We will continue to seek case histories for future volumes because I believe these successes are some of the most instructive stories in medicinal chemistry.

It is also gratifying to see the breadth of the sources of the reviews in Volume 44. My colleagues at Bristol-Myers Squibb continue to embrace the series with seven contributions in Volume 44. Scientists from Pfizer and AstraZeneca each contributed three chapters to Volume 44, while Arena Pharmaceuticals and Novartis each contributed two chapters. Wyeth, Neuraxon, Schering-Plough, Johnson&Johnson, CV Therapeutics, Exelixis, Lexicon Pharmaceuticals and Gilead scientists each contributed one chapter to Volume 44. Finally, chapters from Alfred University, the University of Illinois and an individual consultant completed the line up for Volume 44. I will continue to look to increase the diversity of contributing organizations and urge those organizations with significant medicinal chemistry resources who have not contributed recently to "step up to the plate" and contribute to this community resource known as *Annual Reports in Medicinal Chemistry*. Although we all worry about the mergers and resulting contractions of medicinal chemistry departments, we remain a vibrant science, and I am confident that *Annual Reports in Medicinal Chemistry* will continue to receive the quality contributions that have defined this series for over 40 years.

Putting together *Annual Reports in Medicinal Chemistry* is a team effort of volunteers, starting with the chapter authors themselves. I thank the contributors to Volume 44 for their dedication and talent. Helping bring

this all together are the Section Editors: Joel Barrish, Manoj Desai, John Lowe, David Myles, John Primeau, Albert Robichaud and Andrew Stamford. I thank them for yet another seamless quality effort. Helping them and me were a team of reviewers/proof readers that have done a spectacular job behind the scenes as well. I acknowledge these reviewers/proof readers by listing their names below as a demonstration of our appreciation for their time and effort.

*AstraZeneca* — Mike Barbachyn and Brian Sherer

*Bristol-Myers Squibb* — Stephen Adams, Joanne Bronson, James Corte, Andrew Degnan, Murali Dhar, Douglas Dischino, James Duan, Carolyn Dzierba, Rick Ewing, Matthew Hill, John Hynes, George Karageorge, Lawrence Marcin, Ivar McDonald, Harold Mastalerz, Michael Miller, Natesan Murugesan, Richard Olson, Kenneth Santone, Michael Sinz, Lawrence Snyder, John Starrett, Drew Thompson, Dolatrai Vyas, Michael Walker and Christopher Zusi

*Gilead Sciences* — Randall Halcomb, Richard Mackman and Will Watkins

*Novartis* — Lawrence Hamann

*Pfizer* — Joe Brady and Joel Morris

*Schering-Plough* — Brian McKittrick

*Wyeth* — Jonathan Gross, Steven O'Neil and Dane Springer

Finally, I also acknowledge Shridhar Hedge and Michelle Schmidt for compiling the "To Market, To Market" review once again. I see that section as one of the consistent highlights of the book. And last, I also thank Ms. Catherine Hathaway, my Administrative Assistant, who always keeps things on an even keel.

In summary, I hope that Volume 44 of *Annual Reports in Medicinal Chemistry* continues to be a key reference for your medicinal chemistry pursuits. As Editor-in-Chief, I continue to look for ways to optimize, improve and evolve the series. Please do not hesitate to contact me with suggestions for improving the series ([john.macor@bms.com](mailto:john.macor@bms.com)). Thank you.

John E. Macor  
*Bristol-Myers Squibb, R&D,*  
*Wallingford, CT, USA*



# CONTENTS

<i>Contributors</i>	xv
<i>Preface</i>	xvii

## PART I: Central Nervous System Diseases

Section Editor: Albert J. Robichaud, Chemical & Screening Sciences, Wyeth Research, Princeton, New Jersey

### 1. Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease 3

Robert G. Gentles, Shuanghua Hu and Gene M. Dubowchik

1. Introduction	4
2. Etiology of Alzheimer's Disease	4
3. Principal Functions of GSK-3	5
4. Additional Neuroprotective Indications for GSK-3 Inhibition	8
5. Selective Functional Inhibition of GSK-3	8
6. GSK-3 Isoforms	9
7. GSK-3 Crystal Structures	9
8. Challenges in the Development of Effective GSK-3 Inhibitors	10
9. Advances in GSK-3 Inhibitors	11
10. Conclusion	22
References	23

### 2. Advancements in the Development of Nitric Oxide Synthase Inhibitors 27

Shawn Maddaford, Subhash C. Annedi, Jailall Ramnauth and Suman Rakhit

1. Introduction	27
2. NOS — Structure and Function	28
3. Selective NOS Inhibitors	33
4. Clinical Findings with NOS Inhibitors	41
5. Future Directions — Dual Action NOS Inhibitors	43
6. Conclusions	46
References	47

<b>3. Small-Molecule Protein–Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions</b>	<b>51</b>
Simon N. Haydar, Heedong Yun, Roland G.W. Staal and Warren D. Hirst	
1. Introduction	52
2. A $\beta$ Aggregation and Oligomers in Alzheimer's Disease	53
3. Tau Aggregation in Alzheimer's Disease	58
4. $\alpha$ -Synuclein Aggregation in Parkinson's Disease	63
5. Conclusion	65
References	66
<b>4. Case History: Chantix™/Champix™ (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid</b>	<b>71</b>
Jotham W. Coe, Hans Rollema and Brian T. O'Neill	
1. Introduction	72
2. Partial Agonists at Nicotinic ACh Receptors	74
3. The Search for Partial Agonists: Cytisine as a Key Starting Point	77
4. Semi-Synthetic Analogs of Cytisine	80
5. Cytisine Synthesis and Early Template Expansion	84
6. Discovery of the Bicyclic Benzazepine Core	87
7. Fused Bicyclic Benzazepines	92
8. <i>In vivo</i> Efficacy of Partial Agonists	93
9. Properties of Varenicline	95
10. Clinical Studies	98
11. Conclusions	98
References	99

## PART II: Cardiovascular and Metabolic Diseases

Section Editor: Andy W. Stamford, Schering-Plough Research Institute, Kenilworth, New Jersey

<b>5. Case History on Tekturna®/Rasilez® (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension</b>	<b>105</b>
Jürgen Maibaum and David L. Feldman	
1. Introduction	106
2. Rationale for the Use of Direct Renin Inhibitors	106
3. Pre-Clinical Models to Study Direct Renin Inhibitors	107
4. Medicinal Chemistry Evolution — The Early Renin Inhibitor Program at Ciba-Geigy	108
5. First Convergent and Scalable Synthesis Development	121

6. Pre-Clinical Properties of Aliskiren	122
7. Effects of Aliskiren in Disease Models	123
8. Clinical Studies with Aliskiren	123
9. Conclusions	124
References	124
<b>6. Advances in Vasopressin Receptor Agonists and Antagonists</b>	<b>129</b>
Thomas Ryckmans	
1. Introduction	130
2. V1a Receptor Antagonists	131
3. V1b Receptor Antagonists	134
4. V2 Receptor Agonists	139
5. V2 Receptor Antagonists	140
6. Dual V1a-V2 Receptor Antagonists	141
7. Summary	143
References	144
<b>7. The Emergence of GPR119 Agonists as Anti-Diabetic Agents</b>	<b>149</b>
Robert M. Jones and James N. Leonard	
1. Introduction	149
2. Discovery and Characteristics of GPR119	150
3. The Biology of GPR119	151
4. GPR119 Agonists: Medicinal Chemistry	154
5. Clinical Trial Status and Future Prospects	166
References	167
<b>8. Non-Peptide Ligands for the Gonadotropin Receptors</b>	<b>171</b>
Nicole van Straten and Marco Timmers	
1. Introduction	171
2. Non-Peptide Small Molecule Gonadotropin Receptor Ligands	173
3. Therapeutic Indications and Clinical Findings	182
4. Conclusions and Future Prospects	184
References	185
<b>9. Recent Advances in Coagulation Serine Protease Inhibitors</b>	<b>189</b>
Joanne M. Smallheer and Mimi L. Quan	
1. Introduction	189
2. Factor Xa Inhibitors	190
3. Thrombin Inhibitors	195
4. Factor VIIa/TF Inhibitors	199
5. Factor IXa and XIa Inhibitors	201
6. Conclusions	203
References	203

## PART III: Inflammation/Pulmonary/GI

Section Editor: Joel C. Barrish, Bristol-Myers Squibb R&D, Princeton, New Jersey

<b>10. Advances in the Discovery of Anti-Inflammatory FMS Inhibitors</b>	<b>211</b>
Carl L. Manthey and Mark R. Player	
1. Introduction	211
2. Recent FMS Inhibitors	215
3. Conclusion	221
References	222
<b>11. Recent Advances in the Discovery of CB<sub>2</sub> Selective Agonists</b>	<b>227</b>
Sangdon Han, Jayant Thatte and Robert M. Jones	
1. Introduction	227
2. Evaluation of CB <sub>2</sub> Agonists In Preclinical Models	228
3. Medicinal Chemistry	232
4. Clinical Trials Status	241
5. Conclusions	242
References	243
<b>12. Advances in the Discovery of Small Molecule JAK3 Inhibitors</b>	<b>247</b>
Stephen T. Wroblewski and William J. Pitts	
1. Introduction	247
2. Rationale for Selective Targeting of JAK3 in Inflammatory Diseases	248
3. Clinical Trials and Supporting Preclinical Data	250
4. Challenges in Designing Selective JAK3 Inhibitors	253
5. Recent Medicinal Chemistry Efforts	255
6. Conclusions	261
References	261
<b>13. Recent Advances in Adenosine Receptor (AR) Ligands in Pulmonary Diseases</b>	<b>265</b>
Rao Kalla and Jeff Zablocki	
1. Introduction	265
2. A <sub>1</sub> Adenosine Receptor Antagonists: L-97-1, BG-9928, FK-838, and WRC-0571	266
3. A <sub>2A</sub> Adenosine Receptor Agonists: CGS-21680, UK-371104, and GW-328276	268
4. A <sub>2B</sub> Adenosine Receptor Antagonists: CVT-6883, MRE 2029-F20, LAS-38096, and OSIP-P339391	270
5. A <sub>3</sub> Adenosine Receptor Antagonists: MRS-1523, KF-26777, and MRE-3008-F20	272
6. Summary	274
References	275

## PART IV: Oncology

Section Editor: David C. Myles, Olema Pharmaceuticals, Inc., San Francisco, California

<b>14. Recent Progress in the Development of Small Molecule Inhibitors of Insulin-Like Growth Factor-1 Receptor Kinase</b>	<b>281</b>
Mark D. Wittman, Upender Velaparthi and Dolatrai M. Vyas	
1. Introduction	281
2. IGF-1R Signaling	283
3. ATP-Competitive Inhibitors	284
4. Non ATP-Competitive Inhibitors	293
5. Conclusions	295
References	296
<b>15. Case History: Discovery of Ixabepilone (IXEMPRA™), a First-in-Class Epothilone Analog for Treatment of Metastatic Breast Cancer</b>	<b>301</b>
Robert M. Borzilleri and Gregory D. Vite	
1. Introduction	302
2. Epothilone Natural Products	302
3. Approaches to Identify Drug Candidates	305
4. Preclinical Pharmacology	311
5. Clinical Results	315
6. Future Directions	317
7. Conclusions	319
References	319
<b>16. Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics</b>	<b>323</b>
Stefan Peukert and Karen Miller-Moslin	
1. Introduction	323
2. Mechanism of Hedgehog Pathway Signaling	324
3. Inhibitors of the Hedgehog Pathway	325
4. Hedgehog Inhibitors in Clinical Trials	332
5. Conclusions	333
References	334
<b>17. Emerging Therapies Based on Inhibitors of Phosphatidylinositol-3-Kinases</b>	<b>339</b>
John M. Nuss, Amy Lew Tshako and Neel K. Anand	
1. Introduction	339
2. Inhibitors of PI3Ks: Early Studies	341
3. Clinically Investigated Pan-Active Class I PI3K Inhibitors	343
4. Additional Pan-Active Class I PI3K Inhibitors	347
5. Clinically Investigated Isozyme-Selective PI3K Inhibitors	347

6. Pre-Clinical Isozyme-Selective PI3K Inhibitors	349
7. Conclusions	350
References	351

## PART V: Infectious Diseases

Section Editor: John L. Primeau, Astra Zeneca Waltham, Massachusetts

### 18. The Anti-Infective and Anti-Cancer Properties of Artemisinin and its Derivatives 359

Christopher Paul Hencken, Alvin Solomon Kalinda and  
John Gaetano D'Angelo

1. Introduction	359
2. Antiparasitic Uses of Artemisinin	360
3. Other Therapeutic Uses of Artemisinin	370
4. Toxicity	373
5. Conclusion	375
References	375

### 19. Recent Advances in the Inhibition of Bacterial Type II Topoisomerases 379

Gregory S. Bisacchi and Jacques Dumas

1. Introduction	379
2. Inhibition at the ATP-Binding Site	381
3. Inhibition Outside of the ATP-Binding Site	388
4. Conclusion	393
References	393

### 20. Progress towards the Discovery and Development of Specifically Targeted Inhibitors of Hepatitis C Virus 397

Nicholas A. Meanwell, John F. Kadow and  
Paul M. Scola

1. Introduction	397
2. Specifically Targeted Inhibitors of HCV	398
3. Conclusions	427
References	428

## PART VI: Topics in Biology

Section Editor: John Lowe, JL3Pharma LLC, Stonington, Connecticut

### 21. Inhibitors of Nuclear Hormone Receptor/Coactivator Interactions 443

Terry W. Moore and John A. Katzenellenbogen

1. Introduction	443
2. Coregulators of Nuclear Hormone Receptors	445

3. Coactivator Binding Inhibitors	445
4. Summary	455
References	455
<b>22. Safety Testing of Drug Metabolites</b>	<b>459</b>
Thomas N. Thompson	
1. Introduction	460
2. Evolution of the MIST Guidance	462
3. Potential Issues Related to Implementation of a Sound MIST Strategy	465
4. Implications of Metabolism in Safety Testing of New Drugs	466
5. Strategy for Implementation of Best Practices	467
6. Role of the Medicinal Chemist	472
7. Summary	472
References	473
Appendix: Decision Tree Flow Diagram	474
<b>23. A Path to Innovation: Gene Knockouts Model New Drug Action</b>	<b>475</b>
Brian P. Zambrowicz and Arthur T. Sands	
1. Introduction	475
2. Metabolism	477
3. Gastrointestinal	478
4. Cardiovascular	479
5. Immunology/Hematology	481
6. Rare Genetic Diseases	484
7. Oncology/Ophthalmology	485
8. Central Nervous System	487
9. Can Mouse Knockout Data Guide New Drug Discovery?	488
References	491

## **PART VII: Topics in Drug Design and Discovery**

Section Editor: Manoj C. Desai, Gilead Sciences, Inc., Foster City, California

<b>24. Discovery of Novel Positron Emission Tomography Tracers</b>	<b>501</b>
Dennis J. McCarthy, Christer Halldin, Jan D. Anderson and M. Edward Pierson	
1. Introduction	501
2. PET Imaging	502
3. Discovery of a New PET Tracer for Serotonin 5-HT <sub>1B</sub>	502
4. Steps Needed to Develop PET Tracers	506
5. PET Tracers as Translational Tools	508
6. New PET Tracers	509
7. Conclusions	511
References	512

<b>25. The Use of Isotopically Labeled Compounds in Drug Discovery</b>	<b>515</b>
Charles S. Elmore	
1. Introduction	515
2. Synthesis of Radiolabeled Compounds	518
3. Human ADME Studies	530
4. Conclusions	532
References	532
<b>26. Mechanism-Based Inhibition of CYP3A4 and Other Cytochromes P450</b>	<b>535</b>
Bernard P. Murray	
1. Introduction	535
2. Reversible, Irreversible, and Quasi-Irreversible Mechanism-Based Inhibition	536
3. Practical Determination	539
4. Inhibition of Cytochromes P450	543
5. Clinical Relevance	549
6. Conclusions	551
Acknowledgments	551
References	551
<b>27. Nonclinical Toxicogenomics in the Pharmaceutical Environment</b>	<b>555</b>
William R. Foster, Stefan U. Ruepp and Bruce D. Car	
1. Introduction	556
2. Evaluation of Liver Toxicogenomics	556
3. Transcriptional Markers of Pharmacology	557
4. Deriving Diagnostic Transcriptional Signatures as Biomarkers	559
5. Percentage Global Transcriptional Change with Drug Treatment	559
6. Correlating Transcriptomics with Histopathology	561
7. Transcriptional Changes Associated with General Toxicity	563
8. Ruling in and out Mechanisms of Toxicity with Toxicogenomics	563
9. Assigning Cause or Effect to Transcriptional Alterations	565
10. Critical Assessment of <i>In Vitro</i> Toxicogenomics Applications	566
11. Transcriptional Responses to Diet	567
12. Toxicogenomics, Genotoxicity, and Carcinogenicity Prediction	569
13. Providing Feedback to Discovery Working Groups	570
14. Conclusion	571
References	572
<b>PART VIII: To Market, To Market: Drugs Introduced in 2008</b>	
<b>28. To Market, To Market — 2008</b>	<b>577</b>
Shridhar Hegde and Michelle Schmidt	
1. Introduction	578
2. Alvimopan (Postoperative Ileus) [4–8]	584



3. Biolimus Drug-Eluting Stent (Anti-Restenotic) [9–13]	586
4. Blonanserin (Antipsychotic) [14–17]	587
5. Ceftobiprole Medocaril (Antibiotic) [18–21]	589
6. Certolizumab Pegol (Crohn's Disease) [22–25]	592
7. Choline Fenofibrate (Dyslipidemia) [26–29]	594
8. Clevidipine (Antihypertensive) [30–34]	596
9. Dabigatran Etexilate (Anti-Coagulant) [35–38]	598
10. Desvenlafaxine (Antidepressant) [39–43]	600
11. Etravirine (Antiviral) [44–48]	602
12. Fesoterodine (Overactive Bladder) [49–54]	604
13. Fosaprepitant Dimeglumine (Antiemetic) [55–57]	606
14. Icatibant (Hereditary Angiodema) [58–60]	608
15. Lacosamide (Anticonvulsant) [61–63]	610
16. Methylnaltrexone Bromide (Opioid-Induced Constipation) [64–66]	612
17. Pirfenidone (Idiopathic Pulmonary Fibrosis) [67–70]	614
18. Rilonacept (Genetic Autoinflammatory Syndromes) [71–73]	615
19. Rivaroxaban (Anticoagulant, Venous Thromboembolism) [74–75]	617
20. Romiplostim (Antithrombocytopenic) [76–78]	619
21. Sitafloracin Hydrate (Antibacterial) [79–82]	621
22. Sugammadex (Reversal of Neuromuscular Blockade) [83–87]	623
23. Tafluprost (Antiglaucoma) [88–90]	625
24. Thrombin Alfa (Hemostat) [91–92]	627
25. Thrombomodulin (Recombinant) (Anticoagulant) [93–95]	628
References	630

<b>COMPOUND NAME, CODE NUMBER AND SUBJECT INDEX, VOLUME 44</b>	<b>635</b>
--	------------

<b>CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUME 1–44</b>	<b>645</b>
---	------------

<b>CUMULATIVE NCE INTRODUCTION INDEX, 1983–2008</b>	<b>667</b>
---	------------

<b>CUMULATIVE NCE INTRODUCTION INDEX, 1983–2008 (BY INDICATION)</b>	<b>691</b>
---	------------

**Color Plate Section at the end of this book**